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Abstract
Circadian disruption has been linked with inflammation, an established cancer risk factor. Per3 clock
gene polymorphisms have also been associated with circadian disruption and with increased cancer
risk. Patients completed a questionnaire and provided a blood sample prior to undergoing a
colonoscopy (n = 70). Adjusted mean serum cytokine concentrations (IL-6, TNF-alpha, gamma-INF,
IL-I ra, IL-I-beta, VEGF) were compared among patients with high and low scores for fatigue
(Multidimensional Fatigue Inventory), depressive symptoms (Beck Depression Inventory II), or
sleep disruption (Pittsburgh Sleep Quality Index), or among patients with different Per3 clock gene
variants. Poor sleep was associated with elevated VEGF, and fatigue-related reduced activity was
associated with elevated TNF-alpha concentrations. Participants with the 4/5 or 5/5 Per3 variable
tandem repeat sequence had elevated IL-6 concentrations compared to those with the 4/4 genotype.
Biological processes linking circadian disruption with cancer remain to be elucidated. Increased
inflammatory cytokine secretion may playa role.
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Factors that disrupt circadian rhythms, for example, shift work or altered clock gene expression,
are emerging as novel cancer risk factors. 1-4 Circadian rhythm disruption can lead to the
development of fatigue, sleep disruption, and depressive symptoms, and these psychological
perturbations have been associated with increased secretion of inflammatory cytokines.5-10
Chronic inflammation is an established risk factor for several types of cancer.11,12 Thus, the
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putative association between circadian disruption and cancer may be driven, at least in part,
by immune system dysregulation and changes in the secretion of cytokines that influence
inflammation or tumor development. Similarly, polymorphic variation in certain clock genes
can result in the phenotypic expression of symptoms related to circadian rhythm disruption,
including disrupted sleep and altered mood. 13,14 More recently, certain clock gene
polymorphisms have been associated with increased cancer risk 15-18 The human Per3 clock
gene is a putative tumor suppressor gene that contains a polymorphic domain expressing 4 or
5 copies of a 54-bp tandem repeat sequence. Variation in this sequence has been associated
with circadian preference, sleep and mood disorders, and increased breast cancer risk among
premenopausal women. 18-24 Rhythmic changes in Per and other clock genes have been linked
with regulation of the innate immune system.25-27 However, no study has examined whether
variation in the human Per3 clock gene is associated with altered cytokine secretion. The
objective of this study was to test the hypothesis that individuals with fatigue, poor sleep,
depressive symptoms or a Per3 clock gene variant genotype have altered serum concentrations
of cytokines that can influence inflammation or growth regulation.

Materials and Methods
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The study population consisted of male veterans scheduled for a screening or diagnostic
colonoscopy at the Dom Veterans Affairs Medical Center (DVAMC) in Columbia, South
Carolina. Data were collected from March through November 2007 between 9:00 AM and 5:00
PM. Following informed consent, participation included a personal interview and collection
of a peripheral blood sample for recovery of serum and DNA. All data were collected prior to
completion of the colonoscopy; therefore, participants had no knowledge of the procedure
outcome at the time of interview. The questionnaire included information on sociodemographic
characteristics, lifestyle, diet, employment and shift work, health status, medications and
supplements, mental and physical well-being, physical activity,28 time spent outdoors, risk
factors for colorectal polyps and cancer, sleep habits, major life events, stress and coping
strategies, social support, and validated instruments targeting sleep disruption (Pittsburgh
Sleep Quality Index [PSQI]),29 fatigue (Multidimensional Fatigue Inventory [MFI]),30 and
depressive symptoms (Beck Depression Inventory II [BDI]).31,32 The study was approved by
the institutional review boards of the DVAMC and University of South Carolina.
Whole blood samples used for DNA recovery were collected in ethylenediaminetetraacetic
acid–preserved vacutainers and stored in 0.5-mL aliquots at –80°C prior to analysis. Genomic
DNA was extracted using the DrGentle protocol (Takara, Japan). After extraction, genomic
DNA pellets (50-100 μg) were dissolved in 100 to 200 μL of TE buffer, of which about 200
ng was subjected to polymerase chain reaction (PCR) using a Perkin Elmer GeneAmp System
9700 (Waltham, MA) according to the manufacturer's protocol. The Per3 variable number
tandem repeat (VNTR) DNA sequence was amplified using the following primers (forward)
5′-CAAAATTTTATGACACTACCAGAATGGCTGAC-3′ and (reverse) 5′AACCTTGTACTTCCACATCAGTGCCTGG-3′, with a reaction mixture consisting of 25
μL standard PCR buffer, 5% DMSO, 1.0 mM MgC12, 0.2 mM dNTP, 1 unit Taq polymerase
(Gibco-Invitrogen, Carlsbad, CA), and 0.4 μM of each oligonucleotide primer. The reactions
were heated to 94°C for 2 minutes followed by 35 cycles at 94°C for 30 seconds, 60°C for 30
seconds, and 72°C for 45 seconds. Finally, the reactions were extended for 7 minutes at 72°C.
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PCR products were then separated by electrophoresis on a 3% agarose gel to identify
homozygous (4-repeat: 4/4), 5-repeat (5/5), or heterozygous (4/5) individuals. Laboratory
personnel were blinded to the identity and characteristics of participants, and a 10% random
sample was reanalyzed to assess genotyping concordance.
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Following collection of a nonfasting venous whole blood sample in a red-top vacutainer, serum
samples were clotted at room temperature for 15 to 30 minutes, centrifuged (5000 × g for 5
minutes at 4°C), and 0.5-mL serum aliquots were stored at –80°C until analysis. Serum cytokine
concentrations (interferon [IFN]-γ, tumor necrosis factor [TNF]-α, interleukin [IL]-6, IL-1ra,
IL-1-β, vascular endothelial growth factor [VEGF]) were determined using a Beadlyte human
multicytokine detection system kit (Bio-Rad, Hercules, CA). Filter bottom ELISA plates were
rinsed with 100 μL of Bio-plex assay buffer. The assay buffer was then removed using a
Millipore Multiscreen Separation Vacuum Manifold System (Bedford, MA) set at 5 mm Hg.
Analyte beads in assay buffer were then added to the wells followed by 50 μL of serum or
standard solution. The plates were incubated for 30 minutes at room temperature with
continuous shaking using a Lab-Line Instrument Titer Plate Shaker (Melrose, IL). The filter
bottom plates were washed and centrifuged as before at 300 × g for 30 seconds. Subsequently,
50 μL of antihuman IFN-γ, TNF-α, IL-6, IL-1ra, IL-1-β, or VEGF antibody–biotin reporter
solution was added to each reaction well, after which the plates were incubated with continuous
shaking for 30 minutes followed by centrifugation and washing. Following this, 50 μL
streptavidin–phycoerythrin solution was added, and the plates were incubated with continuous
shaking for 10 minutes at room temperature. Next, 125 μL of Bio-plex assay buffer was added,
and Beadlyte readings were measured using a Luminex System (Austin, TX) and calculated
using Bioplex software. Samples below the limit of detection were assigned a value of one half
the limit of detection (0.25) pg/mL for data analyses.
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Data analyses were performed using the SAS statistical software package (Version 9.l, SAS
Institute Inc, Cary, NC). Values for IL-6, TNF-α, INF-γ, IL-1ra, and IL-l-β were logtransformed prior to analysis, and mean concentrations were transformed back to original units
for presentation. VEGF and psychosocial measures (BDI, MFI, and PSQI scores) were
analyzed without transformation. One participant had elevated TNF-α and INF-γ
concentrations, which were evaluated as potential outliers using the method described by Cook.
33 These concentrations met the criteria for Cook's d statistic33 and were within a physiological
range; thus, the values were retained in the analyses. A 2-step variable selection procedure was
used to identify potential confounding factors associated with each cytokine and psychometric
(MFI, BDI, PSQI) variable. First, each independent variable obtained from the questionnaire
was compared with each dependent variable using the generalized linear models (GLM)
procedure in SAS. Second, screened variables (P < .05) were combined in another GLM model,
and factors that were no longer associated with the dependent variable (P > .10) were removed
sequentially from further analysis. This step was repeated until a set of statistically significant
(P < .05) covariates was identified for each dependent variable, and these were included in
subsequent hypothesis testing analyses. To test the study hypotheses, the GLM procedure was
used to determine whether mean serum cytokine concentrations (IL-6, TNF-α, IFN-γ, IL-1-β,
IL-1ra, and VEGF) differed among individuals grouped according to different circadian
disruption symptoms (using MFI, BDI, or PSQI scores) or among those with different Per3
genotypes. Adjusted (least squares [LS]) mean cytokine concentrations were calculated, and
differences among symptom categories or genotype were determined using the least significant
differences (LSD) statistic, after adjustment for selected potentially confounding factors. BDI
scores were used to group participants into categories of normal (≥10), mild (11-20), or
moderate to severe (≥21) depressive symtoms.32,34 Poor sleepers were defined as those with
PSQI scores ≥5,29,35 and MFI cutpoints were chosen to obtain a distribution of 10 to 15
individuals in several fatigue categories. The relationship between cytokine concentrations and
circadian disruption symptoms was also evaluated using each score as a continuous variable
Integr Cancer Ther. Author manuscript; available in PMC 2010 December 1.
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in separate GLM analyses. The GLM procedure was used to determine whether circadian
disruption symptoms were associated with different Per3 variants by comparing adjusted mean
MFI, BDI, or PSQI scores among the Per3 genotypes. Inclusion of polyp status (no polyp
detected, benign or hyperplastic polyp, adenoma, or unknown—colonoscopy not yet
performed), time of day, or month of sample collection in the statistical analyses did not affect
the results obtained.

Results
A total of 83 eligible subjects participated (participation rate = 45%), and complete data were
available for 70 men (n = 13 with no blood sample). The average age was 57 ± 9 years, and
the racial composition of African Americans and European Americans was approximately
equal (51 % and 49%, respectively). Summary scores for general fatigue (mean ± standard
deviation = 12 ± 2) and depressive symptoms (14 ± 11) among participants were generally
consistent with published normative data (MFI30: 15 ± 7, BDI36: 11 ± 8). The mean global
PSQI score in this population (10 ± 5) was elevated, and a bimodal distribution was suggested,
with scores centering on approximately 5 and 13 (data not shown).
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There were no statistically significant differences in adjusted mean inflammatory cytokine
concentrations between those with adequate and poor quality sleep (Table 1). However, poor
sleep was associated with a statistically significant increase in circulating VEGF concentrations
(P = .04, Table 1). There was no association between serum cytokine concentrations and scores
for depressive symptoms, reduced motivation, or general, physical, or mental fatigue (data not
shown). Participants with higher MFI subscale scores for fatigue-related reductions in activity
tended to have higher TNF-α concentrations compared with those with lower scores (P = .05,
Table 2), although the results were of borderline statistical significance.
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Genotyping for the Per3 VNTR was in Hardy–Weinberg equilibrium (P = .81), and there was
100% concordance with independently genotyped quality control samples. The overall
frequency of the homozygous 5/5 VNTR (10%) or the combined genotype frequency (4/5 and
5/5, 51%) agreed well with previous reports (approximately 7% to 10% and 40% to 54%,
respectively).18,37 Evening circadian preference was reported among 67%, 54%, and 57% of
participants with the 5/5, 4/5, and 4/4 Per3 tandem repeat sequences, respectively. Table 3
presents adjusted mean cytokine concentrations among individuals with different Per3 VNTR
genotypes. Mean IL-6 concentrations were elevated among individuals with the 4/5 or 5/5
VNTR sequence compared with those homozygous for the common (4/4) genotype. Table 4
presents mean scores for sleep, fatigue, and depressive symptoms among those with different
Per3 variant genotypes. A tendency toward reduced motivation and a modest increase in
depressive symptoms was suggested among subjects with the 4/5 or 5/5 genotype, whereas
physical fatigue and sleep disruption tended to be reduced among these individuals compared
with those with the 4/4 genotype (Table 4).

Discussion
Circadian rhythm disruption is emerging as a novel and important cancer risk factor. In
experimental animals, circadian disruption induced by simulated jet lag or via light exposure
at night results in accelerated tumor formation and increased cancer mortality.38-45 Shift work
can have significant impacts on workers; it has been associated with sleep disruption, fatigue,
and, in some cases, depression.46-50 More recently, shift work has been identified as a risk
factor for cancers of the colon, breast, prostate, endometrium, and lymphatic system,1,51-58
and the International Agency for Research on Cancer classified shift work as a probable human
carcinogen.4 The biological mechanisms underlying the association between circadian
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disruption and cancer remain to be fully elucidated but may involve changes in the secretion
of cytokines that control proinflammatory or proliferative processes.
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Results from the present study provide some support for this hypothesis. Poor sleep was
associated with increased serum VEGF concentrations, and mean PSQI scores among our
participants (10 ± 5) were similar to those observed among cancer patients (11 ± 5).35 VEGF
is important among cancer patients because its angiogenic properties support tumor
progression. Additionally, it may affect risk among cancer-free individuals because it can
participate in the development of premalignant lesions such as colonic adenomas.59,60 It has
been suggested that VEGF levels may be elevated in depression,61 a condition frequently
accompanied by poor sleep,62 although there was no association between VEGF and depressive
symptoms in this study. Sleep deprivation has been linked with increased circulating
concentrations of several inflammation mediators, including TNF-α, IFN-γ, IL-6, and IL-l in
humans.7,8,63-66 Results from our study did not support an association between sleep disruption
and circulating inflammatory cytokines, although fatigue-related inactivity was linked with
increased TNF-α concentrations. TNF-α is an established mediator offatigue,9 10 and
therapeutic strategies targeting this cytokine for fatigue reduction are under development.67,
68 Reasons for the inconsistencies among the cytokines measured in this study and results from
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the existing literature may have been due to the inherent variability of the cytokines measured
or due to the cross-sectional nature of the study design. However, we used validated
instruments, and our psychometric measures were generally consistent with normative data.
We were also able to rigorously evaluate and control for numerous potential confounding
factors in the analysis. It may be that multiple, severe, and/or prolonged circadian disruption
symptoms are needed to elicit immune dysfunction and robust changes in circulating cytokine
concentrations. More detailed longitudinal studies with larger samples and quantitative sleep
measures, such as actigraphy or polysomnography, would help in clarifying these issues and
in characterizing potential thresholds of biological dysfunction and disease risk that may be
linked with circadian disruption.
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The molecular clock responsible for human circadian rhythm generation consists of 9 core
clock genes, and their expression has been characterized in virtually every tissue investigated.
2,69-71 Clock genes regulate the timing of DNA repair, apoptosis, and cell proliferation,
processes that are hallmarks of carcinogenesis.2,72,73 About 5% to 15% of genome-wide
mRNA expression exhibits a circadian rhythm that is driven by the clock genes, including some
established tumor suppressor genes and oncogenes.74,75 Mutation or dysregulation of the
Period or other clock genes has been associated with increased cancer susceptibility in several
animal models as well as in human populations.15,17,18,76-80 The Per3 gene has a polymorphic
repeat region with 4 to 5 copies of a 54-bp repetitive sequence in exon 18. This variation results
in an insertion/deletion of 18 amino acids, and it has been linked with sleep and mood disorders
and circadian preference in humans.19-24 A recent breast cancer study found that the 4/5 or 5/5
Per3 VNTR was more common among premenopausal cases (63%) than controls (49%; odds
ratio = 1.7; 95% confidence interval = 1.0-3.0).18 In the present study, individuals with the 4/5
or 5/5 genotype had higher adjusted mean IL-6 cytokine concentrations compared with those
with the 4/4 genotype. IL-6 is a pro inflammatory cytokine involved in tumor progression81
that can induce expression of the Perl clock gene.82 Although the function of human Per3 in
conjunction with IL-6 is currently not known, results from the present study suggest a need for
additional research to determine whether the cancer risks associated with the Per3 VNTR
variant may be related to elevated IL-6 or other inflammatory cytokine concentrations.
In summary, chronic inflammation is a known risk factor for cancer, and symptoms of
depression, fatigue, and sleep disruption are associated with inflammatory cytokine secretion.
However, few studies have attempted to determine whether the association between circadian
disruption and cancer is driven by the secretion of inflammatory cytokines. Results from this

Integr Cancer Ther. Author manuscript; available in PMC 2010 December 1.

Guess et al.

Page 6

NIH-PA Author Manuscript

study suggest that individuals with poor sleep had higher VEGF concentrations compared with
good sleepers, participants with greater fatigue-related inactivity had higher TNF-α
concentrations, and those with a 4/5 or 5/5 Per3 variant genotype had higher mean IL-6
concentrations compared with referents. The results provide some support for the hypothesis
that fatigue, poor sleep, or the Per3 VNTR polymorphism is associated with elevated serum
cytokine concentrations. If a link between circadian disruption and inflammation is established,
therapeutic strategies targeting improved circadian hygiene may provide a benefit by
ameliorating inflammation and reducing cancer risks.
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